Who are Novo Nordisk's key investors?

Key investors in Novo Nordisk include Financial Architects, Scuti Capital Management, and Parvus Asset Management.

How many employees does Novo Nordisk have?

As of Fri, 1 May 2026, Novo Nordisk has approximately 10,001+ employees employees.

How much website traffic does Novo Nordisk receive?

Novo Nordisk receives about 686K monthly website visits in the latest Datakart source snapshot. This helps benchmark market attention, demand generation, and digital reach.

Is Novo Nordisk currently hiring?

Novo Nordisk has 338 open roles in the latest source snapshot. Open job volume can indicate team expansion, budget movement, and active buying needs by department.

What technologies does Novo Nordisk use?

Novo Nordisk's detected technology footprint includes Google Cloud, Apto, Microsoft Intune, Mlflow, Microsoft Excel, Coreldraw. The full profile lists additional verified technologies when available.

Company profile

Pharmaceutical Manufacturing

Novo Nordisk - Company Intelligence Profile

Industry: Pharmaceutical Manufacturing | Founded: 1923 | HQ: bagsværd, Denmark

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.

Datakart tracks firmographic, hiring, traffic, technology, funding, review, and leadership signals for Novo Nordisk to help teams evaluate the account with useful business context.

Public company

Novo Nordisk

novonordisk.com

Employees

63K

Monthly visits

686K

Open roles

338

Search volume

40.5K

View intelligence Start free trial

Company Snapshot

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.

Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com.

This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam.

Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in:

https://www.novonordisk.com/contact-us/find-local-information.html

For other customer complaints, please contact us here:

https://www.novonordisk.com/contact-us.html

Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed.

Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.

Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

1923

Founded

63K

Employee count

686K

Monthly website visits

338

Open roles

Company Snapshot Details

Legal name: Novo Nordisk A/S.

Headquarters: Bagsværd, Denmark

Industry: Pharmaceutical Manufacturing

Sub-sector: Pharmaceutical Manufacturing

Website: https://www.novonordisk.com

YoY headcount growth: not publicly disclosed

Company stage: Public Company

Last updated: Fri, 1 May 2026

Company intelligence

Business signals that help qualify Novo Nordisk

This profile combines firmographic, traffic, hiring, employee, review, compensation, technology, funding, leadership, and product availability signals so visitors can answer practical business questions without hunting across multiple data sources.

Source snapshot

Last refreshed 2026-05-01 | 41K search volume | Domain novonordisk.com

Annual revenue

$44.8B

Reported annual revenue from the source dataset when available.

Quarterly revenue

SEK 75B

Standalone quarterly revenue field from the source dataset.

Monthly visits

686K

Latest monthly visits value available from the source dataset.

Global web rank

#79,415

Lower rank values indicate stronger web visibility in the source dataset.

Employees

63K

Latest employees value available from the source dataset.

Employee reviews

5.4K

Latest employee reviews value available from the source dataset.

-84 monthly (-19.9%)

Hiring demand

338

Open roles reveal which teams may be expanding and where vendor demand can emerge. For Novo Nordisk, this signal is based on the latest available source snapshot.

-458 monthly (-0.7%)

Headcount momentum

63K

Recent employee count movement helps qualify growth, contraction, and operational scale. For Novo Nordisk, this signal is based on the latest available source snapshot.

-2.8M monthly (-100.0%)

Audience growth

2.8M

LinkedIn follower movement is a useful proxy for employer brand, market attention, and hiring reach. For Novo Nordisk, this signal is based on the latest available source snapshot.

+48.3K monthly (+7.6%)

Web demand

686K

Website traffic movement helps benchmark customer interest and go-to-market momentum. For Novo Nordisk, this signal is based on the latest available source snapshot.

0 quarterly

Employee sentiment

4.0

Employee review movement can surface internal confidence, culture stability, and retention risk. For Novo Nordisk, this signal is based on the latest available source snapshot.

Identity atlas

Novo Nordisk identity, aliases, ownership, and taxonomy

This section makes the entity easier to verify: canonical domains, alternate names, descriptions, ownership flags, parent or acquirer context, industry codes, and source-level social reach are grouped together.

Company descriptions

All available company description fields from the source dataset.

Company descriptiondescription

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Enriched descriptionDescription Enriched

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Their purpose is to drive change to defeat diabetes and other serious chronic diseases.

Metadata descriptionDescription Metadata Raw

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.

LinkedIn followers

2.8M

Latest linkedin followers value available from the source dataset.

Owler followers

19.3K

Latest owler followers value available from the source dataset.

Technologies detected

908

Latest technologies detected value available from the source dataset.

Ownership and corporate structure

Ownership status, parent company, acquisition status, and public/B2B flags.

Operating status

Active

Independent Company

Company type

Public Company

type

Ownership status

Public

Ownership Status

Public company

Yes

Is Public

Aliases and domain variants

Company name aliases, website aliases, and canonical domain signals.

Company alias

novo nordisk

Company Name Alias

Company alias

novo nordisk a/s

Company Name Alias

Company alias

novo nordisk a/s.

Company Name Alias

Website alias

https://www.novonordisk.com

Website Alias

Website alias

https://www.novonordisk.com/

Website Alias

Canonical website

https://www.novonordisk.com

website

Website domain

novonordisk.com

Website Domain

Unique website

Yes

Unique Website

Unique domain

Yes

Unique Domain

Expired domain

Expired Domain

LinkedIn shorthand

novo-nordisk

Canonical LinkedIn Shorthand Name

Source ID

2227

Source ID

UUID

1XQZKHVQ3XZJWWY1QGAJJRXTGD

uuid

Industry classification codes

SIC, NAICS, industry, and keyword classification signals.

Industry

Pharmaceutical Manufacturing

industry

Categories and keywords

['healthcare', 'pharmaceuticals', 'insulin', 'obesity', 'rare diseases', 'diabetes', 'chronic diseases', 'global', 'company', 'health', 'drug-development', 'pharma', 'biotechnology', 'health care', 'medical', 'pharmaceutical']

Categories And Keywords

Social follower counts

Follower counts available across LinkedIn, Twitter, and Owler.

LinkedIn followers

2.8M

Followers Count LinkedIn

Owler followers

19.3K

Followers Count Owler

Company locations

Known company locations and office addresses.

Primary location

Novo Alle; Bagsværd, 2880, DK

Office location

32; Bengaluru, Karnataka 560066, IN

Office location

Dubai Healthcare City; Dubai, Dubai, AE

Office location

Avenida Presidente Riesco 5335; Las Condes, Santiago Metropolitan 7550000, CL

Office location

45 Avenue d'Orleans; Chartres, Center 28000, FR

Office location

6300 Dumbarton Circle; Fremont, California 94555, US

Office location

Thurgauerstrasse 36; Zurich, ZH 8050, CH

Office location

Novo Nordisk Park 1; Malov, Capital Region 2760, DK

Social profiles

Official and source-linked social profiles.

Website

https://www.novonordisk.com

https://www.linkedin.com/company/novo-nordisk

Crunchbase

https://www.crunchbase.com/organization/novonordisk

Facebook

https://www.facebook.com/novonordisk

Twitter / X

https://www.twitter.com/novonordisk

Instagram

https://www.instagram.com/novonordisk

YouTube

https://www.youtube.com/@novonordisk

TikTok

https://www.tiktok.com/@novonordisk

Company contact points

Public company-level contact points available in the source dataset.

prindia@novonordisk.com

Phone

24256790

Phone

+45-4444-8888

Phone

45-4444-8888

Financial intelligence

Novo Nordisk revenue, funding, IPO, and acquisition history

Financial signals are grouped as an analyst-style view: revenue sources, income statement rows, funding rounds, acquisition activity, IPO fields, stock listing context, and ownership structure.

Annual revenue

$44.8B

Reported annual revenue from the source dataset when available.

Quarterly revenue

SEK 75B

Standalone quarterly revenue field from the source dataset.

Revenue range

$10B+

Reported annual revenue band from the source dataset.

Total disclosed funding

$78.2M

Sum of disclosed funding round amounts available in the source dataset.

Funding rounds

Number of funding rounds captured in the source dataset.

Acquisitions captured

114

Number of acquisition records captured across the available source columns.

Revenue signals

Annual, quarterly, and range-based revenue signals available in the source dataset.

Source 5

$44.8B

Annual revenue

Source 1SEK 309.1B

Source 4$10B+

Standalone quarterly revenueSEK 75B

IPO and stock listing

IPO date, share price, exchange tickers, and public market identifiers.

IPO date

1981-07-09

IPO Date

Stock tickerNVO

Stock tickerNOVO-B.CO

Latest closing priceSEK 768.80

Ownership and corporate structure

Ownership status, parent company, acquisition status, and public/B2B flags.

Operating status

Active

Independent Company

Company type

Public Company

type

Ownership status

Public

Ownership Status

Public company

Yes

Is Public

Income statement rows

Income statement rows with revenue and profitability metrics where available.

FY, 2025

Fiscal Year

Primary value

Revenue: SEK 309.1B

Additional metrics

Gross profit: SEK 263B; EBITDA: SEK 149.6B; EBIT: SEK 127.6B; Net income: SEK 102.4B; Operating expense: SEK 113.3B; Gross margin: 85.1%; EBITDA margin: 48.4%

Q3, 2025

Primary value

Revenue: SEK 75B

Additional metrics

Gross profit: SEK 64.8B; EBITDA: SEK 31.4B; EBIT: SEK 23.7B; Net income: SEK 20B; Operating expense: SEK 33.4B; Gross margin: 86.5%; EBITDA margin: 41.9%

Q2, 2025

Primary value

Revenue: SEK 76.9B

Additional metrics

Gross profit: SEK 68.8B; EBITDA: SEK 38.3B; EBIT: SEK 33.4B; Net income: SEK 26.5B; Operating expense: SEK 30.5B; Gross margin: 89.6%; EBITDA margin: 49.8%

Q1, 2025

Primary value

Revenue: SEK 78.1B

Additional metrics

Gross profit: SEK 69B; EBITDA: SEK 42.6B; EBIT: SEK 38.8B; Net income: SEK 29B; Operating expense: SEK 26.4B; Gross margin: 88.4%; EBITDA margin: 54.6%

FY, 2024

Fiscal Year

Primary value

Revenue: SEK 290.4B

Additional metrics

Gross profit: SEK 252B; EBITDA: SEK 147.4B; EBIT: SEK 128.3B; Net income: SEK 101B; Operating expense: SEK 104.6B; Gross margin: 86.8%; EBITDA margin: 50.8%

Q3, 2024

Primary value

Revenue: SEK 71.3B

Additional metrics

Gross profit: SEK 62.2B; EBITDA: SEK 36B; EBIT: SEK 33.8B; Net income: SEK 27.3B; Operating expense: SEK 26.2B; Gross margin: 87.2%; EBITDA margin: 50.4%

Q2, 2024

Primary value

Revenue: SEK 68.1B

Additional metrics

Gross profit: SEK 66.6B; EBITDA: SEK 34.8B; EBIT: SEK 25.9B; Net income: SEK 20B; Operating expense: SEK 31.9B; Gross margin: 97.9%; EBITDA margin: 51.1%

Q1, 2024

Primary value

Revenue: SEK 65.3B

Additional metrics

Gross profit: SEK 58.3B; EBITDA: SEK 34.8B; EBIT: SEK 31.8B; Net income: SEK 25.4B; Operating expense: SEK 23.6B; Gross margin: 89.3%; EBITDA margin: 53.2%

FY, 2023

Fiscal Year

Primary value

Revenue: SEK 232.3B

Additional metrics

Gross profit: SEK 202B; EBITDA: SEK 112.1B; EBIT: SEK 102.7B; Net income: SEK 83.7B; Operating expense: SEK 90.1B; Gross margin: 87.0%; EBITDA margin: 48.3%

Q3, 2023

Primary value

Revenue: SEK 58.7B

Additional metrics

Gross profit: SEK 51.6B; EBITDA: SEK 29.4B; EBIT: SEK 26.9B; Net income: SEK 22.5B; Operating expense: SEK 22.2B; Gross margin: 87.9%; EBITDA margin: 50.1%

Q2, 2023

Primary value

Revenue: SEK 54.3B

Additional metrics

Gross profit: SEK 48.6B; EBITDA: SEK 26.1B; EBIT: SEK 23.9B; Net income: SEK 19.4B; Operating expense: SEK 22.5B; Gross margin: 89.5%; EBITDA margin: 48.0%

Q1, 2023

Primary value

Revenue: SEK 53.4B

Additional metrics

Gross profit: SEK 46.9B; EBITDA: SEK 26.7B; EBIT: SEK 25B; Net income: SEK 19.8B; Operating expense: SEK 20.2B; Gross margin: 88.0%; EBITDA margin: 50.1%

Period	Primary value	Additional metrics
FY, 2025 Fiscal Year	Revenue: SEK 309.1B	Gross profit: SEK 263B; EBITDA: SEK 149.6B; EBIT: SEK 127.6B; Net income: SEK 102.4B; Operating expense: SEK 113.3B; Gross margin: 85.1%; EBITDA margin: 48.4%
Q3, 2025 Q3	Revenue: SEK 75B	Gross profit: SEK 64.8B; EBITDA: SEK 31.4B; EBIT: SEK 23.7B; Net income: SEK 20B; Operating expense: SEK 33.4B; Gross margin: 86.5%; EBITDA margin: 41.9%
Q2, 2025 Q2	Revenue: SEK 76.9B	Gross profit: SEK 68.8B; EBITDA: SEK 38.3B; EBIT: SEK 33.4B; Net income: SEK 26.5B; Operating expense: SEK 30.5B; Gross margin: 89.6%; EBITDA margin: 49.8%
Q1, 2025 Q1	Revenue: SEK 78.1B	Gross profit: SEK 69B; EBITDA: SEK 42.6B; EBIT: SEK 38.8B; Net income: SEK 29B; Operating expense: SEK 26.4B; Gross margin: 88.4%; EBITDA margin: 54.6%
FY, 2024 Fiscal Year	Revenue: SEK 290.4B	Gross profit: SEK 252B; EBITDA: SEK 147.4B; EBIT: SEK 128.3B; Net income: SEK 101B; Operating expense: SEK 104.6B; Gross margin: 86.8%; EBITDA margin: 50.8%
Q3, 2024 Q3	Revenue: SEK 71.3B	Gross profit: SEK 62.2B; EBITDA: SEK 36B; EBIT: SEK 33.8B; Net income: SEK 27.3B; Operating expense: SEK 26.2B; Gross margin: 87.2%; EBITDA margin: 50.4%
Q2, 2024 Q2	Revenue: SEK 68.1B	Gross profit: SEK 66.6B; EBITDA: SEK 34.8B; EBIT: SEK 25.9B; Net income: SEK 20B; Operating expense: SEK 31.9B; Gross margin: 97.9%; EBITDA margin: 51.1%
Q1, 2024 Q1	Revenue: SEK 65.3B	Gross profit: SEK 58.3B; EBITDA: SEK 34.8B; EBIT: SEK 31.8B; Net income: SEK 25.4B; Operating expense: SEK 23.6B; Gross margin: 89.3%; EBITDA margin: 53.2%
FY, 2023 Fiscal Year	Revenue: SEK 232.3B	Gross profit: SEK 202B; EBITDA: SEK 112.1B; EBIT: SEK 102.7B; Net income: SEK 83.7B; Operating expense: SEK 90.1B; Gross margin: 87.0%; EBITDA margin: 48.3%
Q3, 2023 Q3	Revenue: SEK 58.7B	Gross profit: SEK 51.6B; EBITDA: SEK 29.4B; EBIT: SEK 26.9B; Net income: SEK 22.5B; Operating expense: SEK 22.2B; Gross margin: 87.9%; EBITDA margin: 50.1%
Q2, 2023 Q2	Revenue: SEK 54.3B	Gross profit: SEK 48.6B; EBITDA: SEK 26.1B; EBIT: SEK 23.9B; Net income: SEK 19.4B; Operating expense: SEK 22.5B; Gross margin: 89.5%; EBITDA margin: 48.0%
Q1, 2023 Q1	Revenue: SEK 53.4B	Gross profit: SEK 46.9B; EBITDA: SEK 26.7B; EBIT: SEK 25B; Net income: SEK 19.8B; Operating expense: SEK 20.2B; Gross margin: 88.0%; EBITDA margin: 50.1%

Funding rounds

Funding history and recent round context.

Post-IPO Equity

2025-06-01 | Parvus Asset Management

Post-IPO Equity

2024-03-01

Post-IPO Equity

$294K

2023-03-01 | Financial Architects

Post-IPO Equity

$55.9M

2022-01-01 | Scuti Capital Management

Post-IPO Equity

$22M

2018-12-05

Post-IPO Equity

1983-03-01

Acquisitions and corporate activity

Acquisitions and corporate activity captured in the source dataset.

Akero Therapeutics, Inc.

$4.7B

2025-10-01 | Acquisition List Source 5

Cardior Pharmaceuticals

$1.1B

2024-03-25 | Acquisition List Source 2

Cardior Pharmaceuticals GmbH

$1.1B

2024-03-01 | Acquisition List Source 5

Athlone

$92.5M

2023-12-14 | Acquisition List Source 2

Alkermes, PLC'S Development And Manufacturing Facility Business in Athlone

$92.5M

2023-12-01 | Acquisition List Source 5

Biocorp

Acquisition

2023-10-11 | Acquisition List Source 1

KBP Biosciences'S Ocedurenone

$1.3B

2023-10-01 | Acquisition List Source 5

Embark Biotech

Acquisition

2023-08-30 | Acquisition List Source 1

Inversago Pharma

Acquisition

2023-08-10 | Acquisition List Source 1

Inversago Pharma, Inc.

$1.1B

2023-08-01 | Acquisition List Source 5

Embark Biotech

$16.3M

2023-08-01 | Acquisition List Source 5

Biocorp

Acquisition

2023-06-05 | Acquisition List Source 2

FORMA Therapeutics

Acquisition

2022-10-14 | Acquisition List Source 1

FORMA Therapeutics

$1.1B

2022-09-01 | Acquisition List Source 2

Dicerna Pharmaceuticals

$3.3B

2021-12-28 | Acquisition List Source 1

Dicerna Pharmaceuticals

$3.3B

2021-11-18 | Acquisition List Source 2

Emisphere Technologies

$1.4B

2020-11-06 | Acquisition List Source 1

Corvidia Therapeutics

$725M

2020-06-15 | Acquisition List Source 1

Corvidia

$725M

2020-06-11 | Acquisition List Source 2

Ziylo

$800M

2018-08-20 | Acquisition List Source 1

Ziylo

Acquisition

2018-08-17 | Acquisition List Source 2

Calibrium

Acquisition

2015-08-27 | Acquisition List Source 1

MB2 LLC

Acquisition

2015-08-27 | Acquisition List Source 1

Xellia Pharmaceuticals

$700M

2013-05-21 | Acquisition List Source 1

Aldaph SpA

Acquisition

2003-10-01 | Acquisition List Source 1

Novo Nordisk Research Center Indianapolis, Inc.

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Denmark A/S

Acquisition

Acquisition List Source 1

Novo Nordisk Service Centre (India) Pvt. Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Pharmatech A/S

Acquisition

Acquisition List Source 1

Novo Nordisk Limited (UK)

Acquisition

Acquisition List Source 1

CS Solar Fund XIV, LLC

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma Sp.z.o.o.

Acquisition

Acquisition List Source 1

Dicerna Pharmaceuticals, Inc.

Acquisition

Acquisition List Source 1

Novo Nordisk Health Care AG

Acquisition

Acquisition List Source 1

Novo Nordisk Inc.

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma EAD

Acquisition

Acquisition List Source 1

Novo Nordisk India Holding Pte Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Farmacêutica do Brasil Ltda.

Acquisition

Acquisition List Source 1

Novo Nordisk Limited Liability Company

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma SAS

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma d.o.o. Belgrade (Serbia)

Acquisition

Acquisition List Source 1

Novo Nordisk Saudi for Trading

Acquisition

Acquisition List Source 1

Novo Nordisk Pharmatech US

Acquisition

Acquisition List Source 1

Novo Nordisk Pharmaceuticals Pty. Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk S.P.A

Acquisition

Acquisition List Source 1

Novo Nordisk US Holdings Inc.

Acquisition

Acquisition List Source 1

Novo Nordisk (Shanghai) Pharma Trading Co., Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Farma dooel

Acquisition

Acquisition List Source 1

Novo Nordisk Scandinavia AB

Acquisition

Acquisition List Source 1

Novo Nordisk Finance (Netherlands) B.V.

Acquisition

Acquisition List Source 1

Novo Nordisk Egypt LLC

Acquisition

Acquisition List Source 1

Novo Nordisk Pars

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma Limited

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma d.o.o.

Acquisition

Acquisition List Source 1

Beijing Novo Nordisk Pharmaceuticals Science & Technology Co., Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Hrvatska d.o.o.

Acquisition

Acquisition List Source 1

Novo Nordisk Pharmaceuticals A/S

Acquisition

Acquisition List Source 1

Forma Therapeutics, Inc.

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma GmbH (Austria)

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma (Thailand) Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Panama S.A.

Acquisition

Acquisition List Source 1

Novo Nordisk (Pty) Limited

Acquisition

Acquisition List Source 1

Novo Nordisk Ltd

Acquisition

Acquisition List Source 1

Novo Nordisk Hungária Kft

Acquisition

Acquisition List Source 1

Novo Nordisk (France)

Acquisition

Acquisition List Source 1

Novo Nordisk Pharmaceutical Services Sp. z.o.o.

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma Operations Sdn Bhd

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma AG

Acquisition

Acquisition List Source 1

Novo Nordisk Production SAS

Acquisition

Acquisition List Source 1

Novo Nordisk Colombia SAS

Acquisition

Acquisition List Source 1

Novo Nordisk Region Europe A/S

Acquisition

Acquisition List Source 1

NNE A/S

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma GmbH (Germany)

Acquisition

Acquisition List Source 1

Novo Nordisk Region China A/S

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma SARL

Acquisition

Acquisition List Source 1

Novo Nordisk Production Support LLC

Acquisition

Acquisition List Source 1

Novo Nordisk Mexico S.A. de C.V.

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma (Private) Limited (Bangladesh)

Acquisition

Acquisition List Source 1

Novo Nordisk (China) Pharmaceuticals Co. Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma S.A.

Acquisition

Acquisition List Source 1

Emisphere Technologies, Inc.

Acquisition

Acquisition List Source 1

Novo Nordisk Limited (Ireland)

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma Gulf FZE

Acquisition

Acquisition List Source 1

Novo Nordisk Farma OY

Acquisition

Acquisition List Source 1

Novo Nordisk Latvia SIA

Acquisition

Acquisition List Source 1

Novo Nordisk Slovakia s.r.o.

Acquisition

Acquisition List Source 1

Novo Nordisk Region Japan & Korea A/S

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma (Taiwan) Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Vietnam Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Estonia OÜ

Acquisition

Acquisition List Source 1

Inversago Pharma Inc.

Acquisition

Acquisition List Source 1

Novo Nordisk Kenya Ltd

Acquisition

Acquisition List Source 1

Novo Nordisk Research Centre Oxford Limited

Acquisition

Acquisition List Source 1

Novo Nordisk Produção Farmacêutica do Brasil Ltda.

Acquisition

Acquisition List Source 1

Novo Nordisk Norway AS

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma, Inc.

Acquisition

Acquisition List Source 1

Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti.

Acquisition

Acquisition List Source 1

Novo Nordisk Farma S.R.L.

Acquisition

Acquisition List Source 1

Novo Nordisk Pharmaceuticals Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Canada Inc.

Acquisition

Acquisition List Source 1

Novo Nordisk North America Operations A/S

Acquisition

Acquisition List Source 1

Novo Nordisk Ukraine, LLC

Acquisition

Acquisition List Source 1

S.A. Novo Nordisk Pharma N.V.

Acquisition

Acquisition List Source 1

Novo Nordisk B.V.

Acquisition

Acquisition List Source 1

Novo Nordisk Peru S.A.C.

Acquisition

Acquisition List Source 1

Aldaph SpA

Acquisition

Acquisition List Source 1

Novo Nordisk Farmacéutica Limitada

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma Korea Ltd.

Acquisition

Acquisition List Source 1

Novo Nordisk Holding Limited

Acquisition

Acquisition List Source 1

Novo Nordisk, d.o.o.

Acquisition

Acquisition List Source 1

PT. Novo Nordisk Indonesia

Acquisition

Acquisition List Source 1

Novo Nordisk Pharma (Malaysia) Sdn Bhd

Acquisition

Acquisition List Source 1

Akero Therapeutics

Acquisition

Acquisition List Source 2

Audience analytics

Web visibility, demand, and topics

Use these signals to understand discoverability, demand quality, search interest, and audience fit.

Monthly visits

686K

Latest monthly visits value available from the source dataset.

Global web rank

#79,415

Lower rank values indicate stronger web visibility in the source dataset.

Bounce rate

48.0%

Latest bounce rate value available from the source dataset.

Pages per visit

2.5

Latest pages per visit value available from the source dataset.

Average visit duration

2m 3s

Latest average visit duration value available from the source dataset.

Estimated monthly page views

1.7M

Derived estimate calculated as monthly visits multiplied by pages per visit.

Website visits

Website visits trend from the latest source snapshots.

LinkedIn followers

LinkedIn followers trend from the latest source snapshots.

Website visits by country

Denmark24.51

United States23.88

India4.9

Sweden3.6

Spain3.6

Employees, hiring, attrition, and compensation

This section groups org scale, hiring motion, employee movement, department mix, and salary benchmarks so teams can qualify operating momentum and budget signals.

Employees

63K

Latest employees value available from the source dataset.

Inferred employees

47.3K

Latest inferred employees value available from the source dataset.

Open roles

338

Latest open roles value available from the source dataset.

Departures

Latest departures value available from the source dataset.

Employee attrition rate

0.0%

Latest employee attrition rate value available from the source dataset.

Hiring intensity

5.4 roles / 1K employees

Derived signal showing open roles normalized by employee count.

Employee headcount

Employee headcount trend from the latest source snapshots.

Inferred employees

Inferred employees trend from the latest source snapshots.

Open job postings

Open job postings trend from the latest source snapshots.

Employee attrition rate

Employee attrition rate trend from the latest source snapshots.

Employee count by department

Other Department6.5K

Operations6.3K

Technical6K

Medical5.7K

Research4.6K

Project Management3.9K

Sales3.4K

Employee count by seniority

Specialist20K

Manager8.3K

Senior8K

Other Management7.7K

Director2.5K

Head910

Partner897

Employee count by region

Northern Europe22.5K

Northern America7.6K

Southern Asia5.1K

Latin America3K

Western Europe2.4K

Southern Europe1.6K

Western Asia1K

Top employee countries

Denmark21.1K

United States7.3K

India4.6K

Brazil1.8K

France1.3K

Italy813

United Kingdom604

Active job openings

Selected open roles that reveal current hiring demand.

Cardiometabolic Care Specialist I - P Poughkeepsie New York

Open role

4355206315

Medical Science Liaison-Hongkong

Open role

4356431400

医药顾问-衡阳-创新胰岛素

Open role

4356431403

Senior/Advanced Project QA Professional

Open role

4356431406

製造オペレーター（郡山工場）

Open role

4356431408

Senior Regulatory Affairs Specialist

Open role

4356491352

Sr. P&O (HR) Manager, Koriyama Factory (KFA)

Open role

4356531373

Regulatory Affairs Manager

Open role

4356561355

Showing 8 of 18 available records.

Where employees came from

Common previous employers visible in employee profile movement.

Sanofi

1.4K employee movements

Internal profile link

Novartis

1.2K employee movements

Internal profile link

Pfizer

1.2K employee movements

Internal profile link

AstraZeneca

1.1K employee movements

Internal profile link

GSK

1K employee movements

Internal profile link

Catalent

972 employee movements

Internal profile link

Københavns Universitet - University of Copenhagen

835 employee movements

Internal profile link

LEO Pharma

824 employee movements

Internal profile link

Showing 8 of 10 available records.

Where employees go next

Common next employers visible in employee profile movement.

AstraZeneca

766 employee movements

Internal profile link

Sanofi

738 employee movements

Internal profile link

Novartis

683 employee movements

Internal profile link

LEO Pharma

635 employee movements

Internal profile link

Eli Lilly and Company

524 employee movements

Internal profile link

Pfizer

515 employee movements

Internal profile link

GSK

471 employee movements

Internal profile link

Novozymes

464 employee movements

Internal profile link

Showing 8 of 10 available records.

Base pay benchmarks

Selected base salary benchmarks from the source dataset.

Analista

BRL $62.9K

Monthly | Updated 2024-09-22

Service Manager

INR $2.5M

Annual | Updated 2024-09-14

Analista Sr

BRL $112.2K

Monthly | Updated 2024-09-14

Associate Key Account Manager

INR $848K

Monthly | Updated 2024-09-14

Gerente De Projetos

BRL $154.3K

Monthly | Updated 2024-09-13

Representante Comercial

BRL $32.4K

Monthly | Updated 2024-09-12

Coordenador

BRL $129.8K

Monthly | Updated 2024-09-10

Chef De Projet

EUR $50.1K

Annual | Updated 2024-09-08

Showing 8 of 10 available records.

Additional pay benchmarks

Selected bonus and additional compensation benchmarks.

Analista

Cash Bonus $5.2K

Monthly | Updated 2024-09-22

Analista Sr

Cash Bonus $19.8K

Monthly | Updated 2024-09-14

Associate Key Account Manager

Cash Bonus $180.9K; Stock Bonus $555.8K; Tips $33.7K

Monthly | Updated 2024-09-14

Service Manager

Cash Bonus $200K

Annual | Updated 2024-09-14

Gerente De Projetos

Cash Bonus $24K; Stock Bonus $15.6K; Profit Sharing $19K

Monthly | Updated 2024-09-13

Representante Comercial

Cash Bonus $752.4K; Profit Sharing $1.8M

Monthly | Updated 2024-09-12

Chef De Projet

Cash Bonus $554.03; Profit Sharing $2.1K

Annual | Updated 2024-09-08

Analista Pleno

Stock Bonus $600K; Profit Sharing $94.7K

Monthly | Updated 2024-09-06

Showing 8 of 10 available records.

Total compensation benchmarks

Selected total compensation benchmarks from the source dataset.

Analista

BRL $62.9K

Monthly | Updated 2024-09-22

Analista Sr

BRL $122.2K

Monthly | Updated 2024-09-14

Associate Key Account Manager

INR $1.3M

Monthly | Updated 2024-09-14

Service Manager

INR $3M

Annual | Updated 2024-09-14

Gerente De Projetos

BRL $161.8K

Monthly | Updated 2024-09-13

Representante Comercial

BRL $875.9K

Monthly | Updated 2024-09-12

Coordenador

BRL $129.8K

Monthly | Updated 2024-09-10

Chef De Projet

EUR $50.7K

Annual | Updated 2024-09-08

Showing 8 of 10 available records.

Product and reputation

Product readiness, customer proof, and employee sentiment

Product availability, public reviews, and employee sentiment help visitors understand whether the company is mature, documented, reviewable, and operationally healthy.

Employee reviews

5.4K

Latest employee reviews value available from the source dataset.

Employee rating

4.0

Latest review score available from the source dataset.

Employee review distribution

Score 52K

Score 41.5K

Score 3703

Score 2258

Score 1222

Employee review score breakdown

Compensation Benefits4.1

Diversity Inclusion4.1

Culture Values4

Work Life Balance4

Career Opportunities3.6

Senior Management3.3

Recommend75.0%

Product availability Q&A

Buyer-facing product availability signals in question-and-answer format.

Is pricing information available?

No. The source snapshot does not list pricing information for this company.

Source availability signal

Is a free trial listed?

No. The source snapshot does not list a free trial for this company.

Source availability signal

Can buyers request a demo?

No. The source snapshot does not list a demo motion for this company.

Source availability signal

Is the product downloadable?

No. The source snapshot does not list downloadable software for this company.

Source availability signal

Are mobile apps listed?

No. The source snapshot does not list mobile apps for this company.

Source availability signal

Is public documentation listed?

No. The source snapshot does not list public documentation for this company.

Source availability signal

Are online reviews listed?

No. The source snapshot does not list online reviews for this company.

Source availability signal

Company graph

Technology, leadership, competitors, funding, and corporate activity

These data points help sales, partnerships, analysts, and researchers understand how the company operates, who surrounds it, and where it may be moving next.

Verified technologies

Detected tools and systems verified in the source dataset.

Google Cloud

Verified technology

Last verified 2026-05-04 | First seen 2024-04-04

Apto

Verified technology

Last verified 2026-05-04 | First seen 2025-08-17

Microsoft Intune

Verified technology

Last verified 2026-05-04 | First seen 2025-02-20

Mlflow

Verified technology

Last verified 2026-05-04 | First seen 2025-08-17

Microsoft Excel

Verified technology

Last verified 2026-05-04 | First seen 2025-02-18

Coreldraw

Verified technology

Last verified 2026-05-04 | First seen 2024-04-22

Qlik Sense

Verified technology

Last verified 2026-05-04 | First seen 2025-02-18

Quentic

Verified technology

Last verified 2026-05-04 | First seen 2026-01-26

Showing 8 of 24 available records.

Market alternatives and competitors

Comparable companies surfaced by the source dataset.

Gilead Sciences

Comparable company

Market alternative

Abbott

Comparable company

Market alternative

Mankind Pharma

Comparable company

Market alternative

Amgen

Comparable company

Market alternative

Roche

Similarity 99,531.0

Market alternative

Sanofi

Similarity 93,311.0

Market alternative

Gilead Sciences

Similarity 76,510.0

Market alternative

Teva

Similarity 86,398.0

Market alternative

Showing 8 of 12 available records.

Leadership and senior operators

Senior employees and operators visible in the source dataset.

Stacey Dameron

Associate Director Human Resources

Becca Ford

Vice President, Aseptic Production & Project Management Office

Samantha Donslund Schwab

Associate Director

Martin Almar Meier

Director, Digital Media Activation

Myriam ZERYA

Social Relations Partner

Miguel Nilsson

Therapeutic Area Head, Clinical Operations Project Management , Rare Disease

Marie Xu

Business Partner

Federica Citro

Technical Department Lead

Showing 8 of 12 available records.

Recent executive arrivals

Recent leadership and senior employee arrival signals.

Miguel Nilsson

Therapeutic Area Head, Clinical Operations Project Management , Rare Disease

Jan 2026

Jef Fensholdt

Global Project Lead

Jan 2026

MRSNZ Asif Siddiqui MICR

Global Medical Affairs Lead, Medical Excellence and Strategic Scientific Communication

Mar 2026

Camillo Montano Dahl

Product Design Lead, NovoCare (IO)

Jan 2026

Sidsel Balsgaard Frølund

Associated Project Director

Jan 2026

Federico Rea

Associate Marketing Director, Region Emerging Markets

Jan 2026

Bitten Troest

VP Quality Coordinator

Dec 2025

Dave Laing

Director, Content & Campaigns

Mar 2026

Recent executive departures

Recent leadership and senior employee departure signals.

Miguel Nilsson

Vice President Clinical Operations, Rare Disease & Advanced Therapies

Dec 2025

Martin Møller

Global Director, Channel Excellence

Feb 2026

Ebrahim Nezamoleslami

Vice President of Finance And Operations

Apr 2026

Wala’ Gammoh

Global Consumer Experience Lead

Mar 2026

Tobias Lannoo

Finance Partner

Apr 2026

Federico Rea

Global Associate Brand Director, Awiqli®

Dec 2025

Louise Hickman

Clinical Operations Lead

Apr 2026

Vojtěch Lode

DSP Group Lead

Dec 2025

Company locations

Known company locations and office addresses.

Primary location

Novo Alle; Bagsværd, 2880, DK

Office location

32; Bengaluru, Karnataka 560066, IN

Office location

Dubai Healthcare City; Dubai, Dubai, AE

Office location

Avenida Presidente Riesco 5335; Las Condes, Santiago Metropolitan 7550000, CL

Office location

45 Avenue d'Orleans; Chartres, Center 28000, FR

Office location

6300 Dumbarton Circle; Fremont, California 94555, US

Office location

Thurgauerstrasse 36; Zurich, ZH 8050, CH

Office location

Novo Nordisk Park 1; Malov, Capital Region 2760, DK

Recent company updates

Recent company update signals from the source dataset.

TIME Magazine has released its ranking of the 100 Most Influential Companies of 2026 - and we are honoured to…

934 reactions; 15 comments

2026-04-30 | TIME Magazine has released its ranking of the 100 Most Influential Companies of 2026 - and we are honoured to be among the disrupters on the list. This recognition reflects a milestone moment - not just for us, but for…

The New England Journal of Medicine just published our phase 3 data on denecimig (Mim8), demonstrating signif…

433 reactions; 1 comments

2026-04-29 | The New England Journal of Medicine just published our phase 3 data on denecimig (Mim8), demonstrating significantly reduced annualised bleeding rate in people with haemophilia A, regardless of inhibitor status, compare…

Food noise is not a choice. Let’s get the facts straight.

308 reactions; 14 comments

2026-04-29 | Food noise is not a choice. Let’s get the facts straight.

We are presenting 52 new abstracts on obesity treatment at the 2026 European Congress on Obesity. This demo…

452 reactions; 8 comments

2026-04-28 | We are presenting 52 new abstracts on obesity treatment at the 2026 European Congress on Obesity. This demonstrates the broadest portfolio of approved and pipeline GLP-1-based therapies. Our new clinical and real-worl…

More than 100 years of scientific innovation – and 30 years of obesity research. During this time, it has be…

98 reactions; 55 comments

2026-04-27 | More than 100 years of scientific innovation – and 30 years of obesity research. During this time, it has become clear to us, that behind every breakthrough, there’s a story of persistence, curiosity and sometimes unex…

Our oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescent…

1.1K reactions; 12 comments

2026-04-23 | Our oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes. Learn more in our press release here: https://lnkd.in/eiAH3EwT #PRESS

Industry classification codes

SIC, NAICS, industry, and keyword classification signals.

Industry

Pharmaceutical Manufacturing

industry

Categories and keywords

Categories And Keywords

Public market signal

Novo Nordisk stock snapshot

TradingView market widget for NYSE:NVO.

NYSE:NVO

Novo Nordisk FAQs

Company profile

Want verified contact data for Novo Nordisk?

Datakart.ai gives you verified email addresses, direct dials, and buying intent signals for key decision-makers at Novo Nordisk and 1,700+ other companies.

Start your free trial Directory